Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...

Amgen shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and rocatinlimab, ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Bank of America Securities analyst Charlie CY Yang has maintained their neutral stance on AMGN stock, giving a Hold rating today. Charlie CY ...

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...

Amgen (AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs rocatinlimab and ...

Cantor Fitzgerald initiated coverage of Amgen with an Overweight rating and $405 price target. The firm views Amgen’s obesity ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Amgen (AMGN – Research Report) yesterday and set a price target of $335.00.